Shield Therapeutics Future Growth
Future criteria checks 2/6
Shield Therapeutics is forecast to grow earnings and revenue by 84.6% and 46.9% per annum respectively while EPS is expected to grow by 104.1% per annum.
Key information
84.6%
Earnings growth rate
104.1%
EPS growth rate
| Pharmaceuticals earnings growth | 21.2% |
| Revenue growth rate | 46.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 72 | N/A | -6 | -1 | 1 |
| 12/31/2025 | 54 | -8 | -7 | -4 | 1 |
| 12/31/2024 | 29 | -22 | -17 | -14 | 2 |
| 6/30/2024 | 21 | -36 | -23 | -21 | N/A |
| 3/31/2024 | 17 | -35 | -32 | -29 | N/A |
| 12/31/2023 | 13 | -33 | -40 | -37 | N/A |
| 9/30/2023 | 10 | -40 | -35 | -33 | N/A |
| 6/30/2023 | 7 | -47 | -30 | -28 | N/A |
| 3/31/2023 | 6 | -49 | -28 | -25 | N/A |
| 12/31/2022 | 5 | -50 | -25 | -23 | N/A |
| 9/30/2022 | 5 | -39 | -27 | -24 | N/A |
| 6/30/2022 | 4 | -30 | -31 | -27 | N/A |
| 3/31/2022 | 3 | -29 | -29 | -26 | N/A |
| 12/31/2021 | 2 | -27 | -27 | -25 | N/A |
| 9/30/2021 | 2 | -22 | -21 | -20 | N/A |
| 6/30/2021 | 3 | -18 | -16 | -16 | N/A |
| 3/31/2021 | 9 | -11 | -9 | -9 | N/A |
| 12/31/2020 | 14 | -4 | -2 | -2 | N/A |
| 9/30/2020 | 13 | -3 | -1 | -1 | N/A |
| 6/30/2020 | 11 | -2 | 0 | 0 | N/A |
| 3/31/2020 | 6 | -6 | -4 | -3 | N/A |
| 12/31/2019 | 1 | -12 | -7 | -5 | N/A |
| 9/30/2019 | 8 | -4 | -1 | 1 | N/A |
| 6/30/2019 | 15 | 3 | 4 | 6 | N/A |
| 3/31/2019 | 15 | 0 | 0 | 3 | N/A |
| 12/31/2018 | 15 | -2 | -4 | 0 | N/A |
| 9/30/2018 | 8 | -13 | -14 | -9 | N/A |
| 6/30/2018 | 1 | -24 | -24 | -19 | N/A |
| 3/31/2018 | 1 | -26 | N/A | -21 | N/A |
| 12/31/2017 | 1 | -26 | N/A | -22 | N/A |
| 9/30/2017 | 1 | -24 | N/A | -21 | N/A |
| 6/30/2017 | 0 | -21 | N/A | -19 | N/A |
| 3/31/2017 | 0 | -19 | N/A | -16 | N/A |
| 12/31/2016 | 0 | -19 | N/A | -13 | N/A |
| 9/30/2016 | 0 | -12 | N/A | -12 | N/A |
| 6/30/2016 | 0 | -4 | N/A | -10 | N/A |
| 3/31/2016 | 0 | -19 | N/A | -8 | N/A |
| 12/31/2015 | N/A | -35 | N/A | -6 | N/A |
| 9/30/2015 | 0 | -41 | N/A | -5 | N/A |
| 6/30/2015 | 0 | -49 | N/A | -4 | N/A |
| 3/31/2015 | 0 | -33 | N/A | -5 | N/A |
| 12/31/2014 | 0 | -20 | N/A | -5 | N/A |
| 12/31/2013 | 0 | -7 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1JS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1JS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1JS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1JS's revenue (46.9% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 1JS's revenue (46.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1JS's Return on Equity is forecast to be high in 3 years time